penicillin F: RN given refers to (2S-(2alpha,5alpha,6beta))-isomer; RN for cpd without isomeric designation not avail 3/91 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6438232 |
| CHEBI ID | 81063 |
| MeSH ID | M0183938 |
| Synonym |
|---|
| flavicidin |
| penicillin f |
| penicillin i |
| 3,3-dimethyl-6-(3-hexenamido)-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid |
| delta(sup 2)-pentenylpenicillin |
| 2-pentenylpenicillin |
| delta-beta,gamma-pentenylpenicillin |
| 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-6-(3-hexenamido)-7-oxo- |
| C17402 |
| 118-53-6 |
| (2s,5r,6r)-6-[[(e)-hex-3-enoyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid |
| 88ey1ap5ur , |
| unii-88ey1ap5ur |
| CHEBI:81063 |
| penicillin f [mi] |
| (2s,5r,6r)-6-((3z)-hex-3-enamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid |
| benzathine benzylpenicillin impurity h [ep impurity] |
| 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-((1-oxo-3-hexen-1-yl)amino)-, (2s,5r,6r)- |
| (2s,5r,6r)-6-((3z)-hex-3-enoylamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid |
| benzylpenicillin sodium impurity g [ep impurity] |
| isopenicillin f |
| benzylpenicillin (benzathine) tetrahydrate impurity h [ep impurity] |
| benzylpenicillin potassium impurity g [ep impurity] |
| DTXSID90151994 |
| Q27155019 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " In both man and rabbit, penicillin X provided higher and more sustained blood levels than did penicillins F or G similarly administered in equal dosage (0." | ( THE VARYING BLOOD LEVELS AFFORDED BY PENICILLINS F, G, K, AND X IN RABBITS AND MAN. Eagle, H, 1947) | 0.23 |
| Class | Description |
|---|---|
| penicillin | Any member of the group of substituted penams containing two methyl substituents at position 2, a carboxylate substituent at position 3 and a carboxamido group at position 6. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 15 (93.75) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (28.62) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 16 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||